Peptides derived from exogenous proteins are presented by both MHC class I and II. Despite extensive study, the features of the endocytic pathway that mediate cross-presentation of exogenous antigens on MHC class I are not entirely understood and difficult to generalize to all proteins. Here, we used dendritic cells and macrophages to examine MHC class I and II presentation of hen egg-white lysozyme (HEL) in different forms, soluble and liposome encapsulated. Soluble HEL or HEL targeted to a late endosomal compartment only allowed for MHC class II presentation, in a process that was blocked by chloroquine and a cathepsin S (CatS) inhibitor; brefeldin A (BFA) also blocked presentation, indicating a requirement for nascent MHC class II. In contrast, liposome-encapsulated HEL targeted to early endosomes entered the MHC class I and II presentation pathways. Cross-presentation of HEL in early endosomal liposomes had several unique features: it was markedly increased by BFA and by blockade of the proteasome or CatS activity, it occurred independently of the transporter associated with antigen processing but required an MHC class I surfacestabilizing peptide, and it was inhibited by chloroquine. Remarkably, chloroquine facilitated MHC class I cross-presentation of soluble HEL and HEL in late endosomal liposomes. Altogether, MHC class I and II presentation of HEL occurred through pathways having distinct molecular and proteolytic requirements. Moreover, MHC class I sampled antigenic peptides from various points along the endocytic route.
D
endritic cells (DCs) and macrophages (Ms) present peptides derived from exogenous antigens on MHC class I and II (1) . The subcellular localization of the antigen processing and MHC loading steps determines the molecular and proteolytic requirements for generation of a particular peptide (2, 3) . In the MHC class II pathway, there is general agreement on the roles for protein synthesis, invariant chain, DM, and endosomal acidification for protein presentation, which differ from those of peptide presentation (1) . Presentation by MHC class I (i.e., cross-presentation) involves unique antigen transport through the endocytic route that may or may not engage the classical MHC class I pathway (4) . For example, the generation of K b -SIINFEKL complexes from ovalbumin (Ova), the most frequently tested protein, required specific components of the MHC class I processing machinery contingent on the form of antigen and the nature of the presenting cell (5, 6) ; some forms of Ova entered the cytosol for proteasomal processing (6) (7) (8) (9) (10) , whereas others did not (5, 11) . Although several recent reports described endosomes/phagosomes facilitating both MHC class I and II presentation, it is unclear if these compartments are unique or even extant (12) .
Previous studies by our laboratory demonstrated that protein encapsulation in liposomes enabled antigen targeting to specific endosomal compartments for processing and presentation on MHC class I and II (13, 14) . Liposomes composed of dioleoylphosphatidylcholine (DOPC) and dioleoyl-phosphatidylserine (DOPS) were stable at acidic pH and released their contents via enzymatic degradation of the liposome membrane; these acidresistant liposomes delivered antigen to late endosomes or lysosomes, facilitating efficient MHC class II presentation. In contrast, liposomes composed of dioleoyl-phosphatidylethanolamine (DOPE) and cholesteryl hemisuccinate (CHEMS) released their contents at pH Ͻ6.5; these acid-labile liposomes delivered antigen to early endosomes and allowed for presentation on both MHC class I and II. By targeting specific endosomes, liposome-encapsulated antigens allow us to examine several aspects of MHC class I and II presentation from different compartments: Is there a mechanistic difference between MHC class II presentation of the same epitope from early and late endosomal compartments? Does MHC class I cross-presentation occur from early or late endosomes, and, if so, what are the requirements? Here, we find distinct requirements for MHC class I and II presentation depending on the form of hen egg-white lysozyme (HEL) offered to the antigen-presenting cell (APC). In addition, HEL and Ova entered remarkably different cross-presentation pathways, implying mechanistic and anatomical heterogeneity among the endosomes that support crosspresentation. T cells; on the  H-2 g7 background, the CD4 T-cell epitope, HEL 11-25, lies adjacent to the CD8 T-cell epitope, HEL 23-31. To elucidate the mechanism(s) by which these 2 epitopes are generated, CD4 and CD8 T-cell hybridomas directed to these 2 peptides were used to measure processing and presentation of exogenous HEL in soluble form or encapsulated in liposomes.
HEL encapsulated in late endosomal liposomes was efficiently processed and presented by MHC class II but not by MHC class I. In contrast, HEL encapsulated in early endosomal liposomes was presented on both MHC molecules ( Fig. 2 A, C , E, and G). Soluble HEL was presented solely on MHC class II. The same results were obtained for peritoneal Ms (Fig. 2 A and E) and splenic DCs (Fig. 2 C and G) . These results agree with previous work from our laboratory demonstrating MHC class I crosspresentation of Ova encapsulated in early (but not late) endosomal liposomes (14) .
Processing and presentation of both endogenous and exogenous antigens often requires nascent MHC molecules (1) . To determine if presentation of liposome-encapsulated HEL by MHC class I and II used newly synthesized molecules, brefeldin A (BFA) was used to block protein transport from the Golgi apparatus. BFA treatment completely blocked MHC class II presentation of HEL encapsulated in early and late endosomal liposomes as well as soluble HEL (Fig. 3 A-C) . In striking contrast, cross-presentation of HEL in early endosomal liposomes was enhanced by BFA treatment (Fig. 3F) ; in 3 independent experiments, BFA increased presentation of 1 M antigen 3.7-fold, 4.5-fold, and 3-fold. As a control, the effect of BFA on cross-presentation of soluble Ova was tested. Consistent with previous reports, BFA-treated APCs did not present soluble Ova on MHC class I (Fig. S2 A) . Together, the BFA-mediated blockade of HEL presentation on MHC class II and Ova presentation on MHC class I indicated that removal of the inhibitor did not allow for de novo antigen processing to normalize presentation to control levels.
Proteasome Inhibitors Augment Cross-Presentation of HEL in Early
Endosomal Liposomes. In the classical MHC class I pathway, cytosolic proteins are catabolized by the proteasome before MHC class I loading. Cross-presentation of exogenous antigens on MHC class I can also involve transport into the cytosol followed by proteasomal processing (4) . Recent data suggest that peptides generated by the proteasome can be loaded on MHC class I in either the endoplasmic reticulum (ER) or endosomes (6) ; loading in the ER is BFA-sensitive, whereas loading in endosomes is BFA-insensitive.
The BFA-mediated enhancement in cross-presentation of HEL in early endosomal liposomes indicated that MHC class I loading with HEL peptide did not occur in the ER. To determine if the proteasome was required for processing of HEL in early endosomal liposomes, Ms were treated with lactacystin before pulsing with HEL. Treatment with lactacystin markedly increased cross-presentation of HEL in early endosomal liposomes (Fig. 4A) ; in 3 independent experiments, lactacystin enhanced presentation of 1 M antigen 4.3-fold, 7.7-fold, and 8.1-fold. Epoxomicin produced a similar effect (Fig. 4B) . Presentation of all other forms of HEL on MHC class I and II was unaffected by proteasome inhibition (Fig.  4 C and D) . In contrast, lactacystin inhibited cross-presentation of soluble Ova, demonstrating that proteasome inhibition was effective under our experimental conditions (Fig. S2 A) . In addition to the proteasome, the cytosolic protease tripeptidyl peptidase II (TPPII) has been implicated in MHC class I presentation (15) . Experiments using a chemical inhibitor of TPPII did not show an effect on cross-presentation of HEL in early endosomal liposomes (Fig. S3A) . Overall, these data indicate that HEL in early endosomal liposomes does not require cytosolic proteolysis for crosspresentation.
Cross-Presentation of HEL in Early Endosomal Liposomes Does Not Require the Transporter Associated with Antigen Processing (TAP).
Cytosolic peptides can be transferred into the ER (4) or endosomes (6) via TAP. Cross-presentation of HEL in early endosomal liposomes was completely abolished in APCs from TAP1 Ϫ/Ϫ mice (Fig. 5A ). Nonetheless, TAP1 Ϫ/Ϫ APCs presented HEL 23-31 peptide, demonstrating that MHC class I could traffic to the cell surface (Fig. 5B ). This result contradicted the previous finding that cytosolic processing was not required. However, it is possible that the presentation defect in TAP1 Ϫ/Ϫ APCs reflected aberrant or limited trafficking of MHC class I rather than a requirement for HEL peptide transport from the cytosol (16) . (17) . In experiment 2 using DCs, LLO 91-99 failed to enable MHC class I presentation (Fig. 5D ). When no exogenous peptide was added, we observed no cross-presentation by TAP1 Ϫ/Ϫ APCs. Altogether, these data imply that traffic of MHC class I, and not peptide transport into the ER, accounted for the apparent TAP dependence for cross-presentation of HEL in early endosomal liposomes.
Endosomal Acidification Differentially Affects MHC Class I and II
Presentation of HEL. Agents that prevent endosomal acidification (e.g., chloroquine) can hinder proteases required for processing and presentation on both MHC class I and II (18, 19) . Pretreatment of Ms with chloroquine inhibited MHC class II presentation of HEL encapsulated in either early or late endosomal liposomes; chloroquine also inhibited MHC class II presentation of soluble HEL (Fig. 6 A-C) . MHC class II presentation of soluble peptide was unaffected by chloroquine (Fig. 6D) .
Chloroquine treatment blocked cross-presentation of HEL in early endosomal liposomes (Fig. 6F) ; in 3 independent experiments, chloroquine reduced presentation by 65-80%. To rule out the possibility that chloroquine was preventing the release of HEL from liposomes, we also examined MHC class I presentation of peptide encapsulated in early endosomal liposomes; chloroquine treatment had no effect on MHC class I presentation of liposome-encapsulated peptide (Fig. S4A) . Together, these results imply that proteolysis within an endosomal compartment generated the MHC class I epitope. Remarkably, chloroquine enabled cross-presentation of soluble HEL and HEL encapsulated in late endosomal liposomes (Fig. 6 E and G) , suggesting that proteolytic destruction of the MHC class I epitope precluded cross-presentation; we observed similar results in 4 independent experiments.
In summary, endosomal acidification is an essential step in HEL processing for MHC class II presentation, regardless of the manner in which HEL is offered to the APCs. Although acidification is required for cross-presentation of HEL in early endosomal liposomes, this process hinders cross-presentation of HEL directed to late endosomal compartments or HEL taken up in soluble form.
Cathepsin Proteases Differentially Affect MHC Class I and II Presentation of HEL. Previous studies implicated cathepsin (Cat) proteases in both MHC class I and II antigen processing and presentation (20) . To determine if particular Cats were involved in processing HEL epitopes for MHC class I and II presentation, inhibitors specific for cysteinyl proteases CatS and CatB/L were tested. MHC class II presentation of soluble HEL and HEL in early and late endosomal liposomes was blocked by CatS inhibition ( Fig. 7A and Fig. S5 A and B) ; in 2 independent experiments, CatS inhibition reduced presentation of 1 M antigen by 60-80%. Presentation of exogenous peptide was unaffected by CatS inhibition (Fig. S5C) , indicating that the effect on HEL liposome presentation was not attributable to a generalized impairment in MHC class II presentation. CatB/L inhibition had no effect on MHC class II presentation of soluble HEL or HEL in late endosomal liposomes but reduced presentation of HEL in early endosomal liposomes (Fig. 7A and Fig. S5 A and B) ; in 2 independent experiments, CatB/L inhibition reduced presentation by 50%. In summary, all forms of HEL required CatS activity for MHC class II presentation. CatB/L inhibition selectively reduces MHC class II presentation of HEL in early endosomal liposomes, indicating that different endosomal compartments use unique proteases for HEL processing.
Surprisingly, cross-presentation of HEL in early endosomal liposomes was augmented by CatS inhibition, whereas CatB/L inhibition had no effect (Fig. 7B) ; in 3 independent experiments, CatS inhibition enhanced presentation of 1 M antigen 2.9-fold, 3.7-fold, and 2.7-fold. We also examined cross-presentation by Ms and DCs from CatS Ϫ/Ϫ B6 mice. Cross-presentation of HEL in early endosomal liposomes was enhanced in the absence of CatS, although to a lesser extent compared with chemical inhibition of CatS.
Discussion
We derive 3 general conclusions from the experiments presented here: (i) MHC class I and II are available to bind HEL peptides in diverse endosomal compartments; (ii) the proteolytic environment dictates the capacity of different endosomal compartments to mediate MHC class I and II presentation of exogenous HEL; and (iii) the nature of the protein, perhaps through its mechanism of uptake, is important in determining the features of cross-presentation. Specifically, our data support the conclusion that soluble HEL and HEL in late endosomal liposomes entered endosomes that rapidly acidified en route to lysosomes equipped only for MHC class II presentation; antigen catabolism precluded cross-presentation in this pathway. Early endosomal liposomes targeted HEL to a slowly acidifying and minimally degradative endosome that permitted antigen processing for MHC class I and II presentation; cross-presentation from this compartment did not require nascent MHC molecules, cytosolic processing, or TAP.
Cross-presentation of HEL in early endosomal liposomes showed a number of unique properties that distinguished it from previously studied proteins and gave us clues on the nature of the processing endosomes (Table S1 ). BFA and proteasome inhibition consistently enhanced cross-presentation; these treatments increased presentation independent of antigen processing, because presentation of liposome-encapsulated peptide was also enhanced (Fig. S5A) . In addition to the Golgi apparatus, endosomal membrane traffic is susceptible to BFA (21). Hence, it is possible that the BFA-mediated enhancement in crosspresentation resulted from the formation or stabilization of a specialized endosomal compartment. The endosomal tubules that form with BFA treatment (21) resemble tubules involved in recycling of MHC class I (22) , suggesting that this compartment may facilitate cross-presentation. It is unclear how proteasome inhibition could enhance processing and presentation of a noncytosolic antigen. It is possible that regulation of MHC class I traffic by ubiquitination (23, 24) in conjunction with proteasome-mediated deubiquitination for proper endosomal sorting (25) could affect certain cross-presentation pathways. Ongoing imaging experiments should clarify the relation between endosomal membrane traffic, MHC class I localization, and crosspresentation. A relation between endosomal acidification and crosspresentation was raised by Amigorena's group (26) , who showed that Ova cross-presentation was favored by neutral pH and low proteolytic activity. Along these lines, we observed crosspresentation of soluble HEL and HEL in late endosomal liposomes only when acidification was blocked by chloroquine; on the other hand, cross-presentation of HEL in early endosomal liposomes required acidification, suggesting productive antigen processing by acid-dependent proteases. Taken together, these results are not contradictory. We speculate that APCs contain a heterogeneous set of endosomes whose proteolytic environments dictate their capacity for MHC class I cross-presentation. The proteolytic environment encountered by soluble HEL and HEL in late endosomal liposomes is biased toward epitope destruction; we are currently investigating if this is the result of more proteolysis in general or exposure to particular proteases that specifically destroy the HEL epitope. In contrast, soluble Ova and HEL in early endosomal liposomes naturally enter compartments where the low proteolytic environment favors cross-presentation (via 2 different mechanisms). For soluble Ova, this entails escape into the cytosol for proteasomal processing; for HEL in early endosomal liposomes, this entails processing and MHC class I loading that takes place entirely within the endosome.
Previous reports using a variety of antigens described crosspresentation pathways involving acid-dependent proteases (19, 27, 28) , especially cysteinyl proteases (5, 29, 30) . In both Ms and DCs, the bulk of cysteinyl protease activity increased with endosomal maturation (31) . Interestingly, the cysteinyl protease CatS exhibited activity at both acidic and neutral pH (32) and localized to endosomes and lysosomes (33) . In our experiments, CatS activity hindered cross-presentation of HEL in early endosomal liposomes, which contrasts with the findings in the report from Rock's group (5) examining cross-presentation of Ova and viral antigens. Altogether, this implies that CatS is poised to generate or destroy antigenic peptides in several endosomal compartments, including those involved in crosspresentation.
The cross-presentation pathways of soluble HEL and Ova are strikingly dissimilar (Table S1) , likely attributable to different uptake mechanisms. Kurts and colleagues (34) demonstrated that the mannose receptor delivered soluble Ova to an endosomal compartment equipped for cross-presentation; in contrast, macropinocytosis of Ova allowed for MHC class II presentation but not cross-presentation. HEL is not glycosylated and is presumably taken up by macropinocytosis when offered in soluble form; HEL can bind to constituents of plasma membranes, such as phospholipids (35) and glycosaminoglycans (36) , but receptor-mediated uptake has not been shown. Our data indicate that soluble HEL rapidly enters late endosomes and does not remain in early endosomes for enough time to allow processing and cross-presentation; this feature of soluble HEL trafficking also hindered MHC class II presentation of type B epitopes, which are generated exclusively in early endosomes lacking the accessory molecule DM (37) .
It is unlikely that all endocytosed proteins will cross into the cytosol from endosomes or, if they do cross, whether they are processed by the MHC class I system. Whether Ova's traffic represents the rule or an exception needs to be evaluated. We have found no evidence that any form of HEL enters the cytosol for cross-presentation. It is unclear if this feature of HEL crosspresentation is antigen-or compartment-specific; that is, transport of HEL protein into the cytosol may be impossible, or HEL may not enter a compartment where translocation into the cytosol is an option. Interestingly, our CD8 T-cell hybridomas do not recognize APCs from mice expressing membrane-bound HEL, even though it is likely that a fraction of membrane-bound HEL enters the cytosol via the ER-associated degradation pathway. Thus, it is possible that HEL processing in the cytosol and/or ER is not conducive to peptide-MHC generation in our system.
Multiple studies indicated that CD8␣ ϩ DCs are the principal cross-presenting APCs in vivo (38, 39) . Moreover, many of the specialized receptors that deliver exogenous antigen to crosspresenting endosomal compartments are highly enriched on or unique to CD8␣ ϩ DCs (40, 41) . The trafficking and biochemical features of these particular endosomes are unknown, but it is likely that specific receptors deliver exogenous antigens to endosomes with low degradative activity. In preliminary experiments, we observed cross-presentation of HEL in early endosomal liposomes by CD8␣-depleted splenic DCs; this is consistent with previous reports (42) and implies that the antigen uptake and processing functions specific to CD8␣ ϩ DCs are dispensable for some modes of cross-presentation. In addition, we and others observed robust cross-presentation by Ms in vitro (14, 34) and in vivo (43) ; notably, 2 recent reports demonstrated that Ms reduced their proteolytic activity and altered their membrane trafficking after exposure to lipopolysaccharide and IFN-␥, insinuating that these cells boost their cross-presenting capacity on activation (44, 45) . Considering all these data, it is likely that specialized receptors, but not specialized endosomal compartments, endow certain APCs with robust cross-presenting ability. We speculate that all cells contain endosomal compartments suitable for cross-presentation; in fact, Cresswell and colleagues (46) recently showed that 293T cells are capable of crosspresentation. Further characterization of the antigen processing and MHC class I loading machinery as well as the types of antigens contained within these endosomal compartments should clarify the mechanisms of cross-presentation.
Materials and Methods
Mice. Nonobese diabetic (NOD), C57BL/6 (B6), B6.H-2 g7 , and B10.BR mice were obtained from The Jackson Laboratory. TAP1 Ϫ/Ϫ mice on the B6 background were obtained from Ted Hansen (Washington University, St. Louis, MO). CatS-deficient mice on the B6 background were obtained from Harold Chapman (University of California, San Francisco, CA). Nondiabetic NOD male mice (8 -10 weeks old) were used for most experiments. B6.H-2 g7 mice yielded identical results. All mice were bred under specific pathogen-free conditions at Washington University in accordance with institutional animal care guidelines.
Antigens. HEL protein was from Sigma and was purified by affinity chromatography to remove contaminants and degraded protein. Purified HEL contained Ͻ0.1 EU/mg LPS. Mass spectrometry analysis indicated no evidence of degraded protein. Ova protein was from Worthington Biochemical. The following peptides were synthesized by Fmoc techniques and verified by mass spectrometry: HEL 11-25 (AMKRHGLDNYRGYSL), HEL 23-31 (YSLGNWVCA), LLO 91-99 (GYKDGNEYI), and Ova 257-264 (SIINFEKL). Flu-NP 366 -374 (ASNENMETM) was obtained from Ted Hansen (Washington University, St. Louis, MO). DOPC, DOPS, and DOPE were from Avanti Polar Lipids and were dissolved in chloroform. CHEMS was from Sigma and was dissolved in chloroform. All lipids were stored under nitrogen at Ϫ20°C. Liposome-encapsulated HEL was prepared as previously described (47) .
Chemical Reagents. BFA, chloroquine, epoxomicin, and lactacystin were obtained from Sigma. Inhibitors of CatB/L (ZZ-FF-FMK), CatS (Z-FL-COCHO), and TPPII (H-AAF-CMK) were obtained from Calbiochem. LysoTracker Red, Texas Red-conjugated transferrin, FITC-and Texas Red-conjugated 10-kD dextran, and Alexa555-conjugated streptavidin were obtained from Invitrogen. Biotinylated K k antibody was obtained from Caltag. Biotinylated I-A k antibody (40F) was generated in our laboratory.
T-Cell Hybridoma Generation. HEL-specific CD4 and CD8 T cells from NOD mice immunized with HEL emulsified in complete Freund's adjuvant (Difco) were fused to BW5147 partner cells to generate T-cell hybridomas (48) . A similar protocol was used for generation of SIINFEKL-specific CD8 T-cell hybridomas from B6 mice immunized with Ova emulsified in complete Freund's adjuvant. Hybridomas were subcloned before use in antigen presentation assays.
Antigen Presentation Assays. Unless otherwise noted, cells were cultured at 37°C/5% CO2 (vol/vol) in DMEM containing antibiotics and 10% (vol/vol) FCS.
CD11c ϩ DCs were obtained from spleens of mice injected with Flt3L-Fc protein using CD11c MACS beads (Miltenyi). Splenic DCs from untreated mice were also used and yielded similar results. Peritoneal Ms were obtained from mice injected with thioglycollate 4 days previously. T-cell assays were performed in 96-well V-bottom (for DCs) or flat-bottom (for Ms) plates. Briefly, 5 ϫ 10 4 DCs per well or 10 5 Ms per well were incubated with or without chemical inhibitors for 30 min before the addition of antigen dose curves. DCs were pulsed with antigen for 4 -6 h, and Ms were pulsed for 12-16 h. Cells were subsequently washed with DMEM, and 5 ϫ 10 4 T-cell hybridomas per well were added. After overnight culture, IL-2 in the supernatant was measured by CTLL-2 3 H-thymidine incorporation.
Confocal Microscopy. DCs and Ms were obtained as described previously and cultured on glass coverslips. To visualize both types of liposomes simultaneously, cells were incubated with FITC-dextran in DOPC/DOPS and Texas Red-dextran in DOPE/CHEMS (50 -100 g/mL each) for 12 h. For colocalization experiments, cells were incubated with 100 g/mL Texas Red-transferrin or 10 nM LysoTracker Red in the presence of liposome-encapsulated FITC-dextran (50 -100 g/mL) for 12 h. For MHC class I and II internalization experiments, cells were incubated at 4°C with 200 ng of biotinylated anti-K k , anti-I-A k , or control IgG for 1 h, followed by Alexa555-conjugated streptavidin for 1 h. After washing with cold PBS, cells were incubated at 37°C with FITC-dextran in DOPC/DOPS or DOPE/CHEMS liposomes (50 -100 g/mL) for 12 h. In all experiments, cells were washed with PBS and mounted on slides; images were acquired using a Zeiss 510 laser scanning confocal microscope.
